Philip Morris stock price target lowered to $166 at UBS on ZYN forecast

UBS has lowered its price target on Philip Morris (PM) to $166 from $177, citing reduced forecasts for its critical ZYN nicotine pouch segment, including cuts to FY25/26 US ZYN can and revenue projections. The firm anticipates ZYN will slightly underperform the broader market due to fragmentation and competitive pressures, which, combined with PM's recent mixed Q2 2025 results (an EPS beat but a revenue miss), signals potential headwinds for the company's future growth trajectory despite its strong year-to-date performance.

Analysis

UBS has revised its outlook on Philip Morris (PM), lowering the price target to $166 from $177 while maintaining a Neutral rating, primarily due to reduced growth expectations for its ZYN nicotine pouch brand. The bank has cut its fiscal year 2025/2026 US ZYN can estimates to 801/922 million and trimmed revenue projections to $2.52/2.76 billion. While the overall US nicotine pouch market is forecast to grow at a 22% CAGR through 2030, UBS projects ZYN will underperform with an 18% CAGR, citing increasing market fragmentation, a narrowing price gap with competitors, and survey data indicating limited brand loyalty. This analyst caution is contextualized by PM's recent mixed Q2 2025 results, which saw an adjusted EPS beat at $1.91 but a revenue miss at $10.14 billion against a $10.31 billion forecast. Despite a strong 36.1% year-to-date return and a robust 66.44% gross profit margin, UBS anticipates PM may deliver results at the lower end of its medium-term range in 2026, with 5.6% organic sales growth, though potential foreign exchange tailwinds could lift reported EPS growth to 11.5%.

Key Decisions for Investors

• Investors should closely monitor ZYN's market share and pricing strategy, as its projected underperformance in a high-growth category represents the primary headwind to Philip Morris's future earnings.
• Given the combination of a recent revenue miss and lowered analyst guidance for ZYN, investors should re-evaluate the risk to the company's growth outlook against its defensive qualities, such as its 18-year history of dividend payments and current 3.35% yield.
• It is prudent to watch for management's commentary in upcoming earnings reports to see if they reaffirm or adjust guidance, particularly in response to the competitive pressures in the nicotine pouch market highlighted by UBS.
• Consider the potential impact of foreign exchange fluctuations, which UBS notes could serve as a tailwind and push reported EPS growth to 11.5%, potentially offsetting some weakness in organic growth.